Glycomics as an innovative technology to identify biomarkers of aging

Introduction. Glycomic analysis allows investigating on the global glycome within body fluids (as serum/plasma), this could eventually lead to identify new types of disease biomarkers, or as in this study, biomarkers of human aging studying specific aging models. Recent studies demonstrated that the...

Full description

Bibliographic Details
Main Author: Borelli, Vincenzo <1984>
Other Authors: Franceschi, Claudio
Format: Doctoral Thesis
Language:en
Published: Alma Mater Studiorum - Università di Bologna 2014
Subjects:
Online Access:http://amsdottorato.unibo.it/6312/
id ndltd-unibo.it-oai-amsdottorato.cib.unibo.it-6312
record_format oai_dc
spelling ndltd-unibo.it-oai-amsdottorato.cib.unibo.it-63122015-03-11T04:50:01Z Glycomics as an innovative technology to identify biomarkers of aging Borelli, Vincenzo <1984> MED/04 Patologia generale Introduction. Glycomic analysis allows investigating on the global glycome within body fluids (as serum/plasma), this could eventually lead to identify new types of disease biomarkers, or as in this study, biomarkers of human aging studying specific aging models. Recent studies demonstrated that the plasma N-glycome is modified during human aging, suggesting that measurements of log-ratio of two serum/plasma N-glycans (NGA2F and NA2F), named GlycoAge test could provide a non-invasive biomarker of aging. Down syndrome (DS) is a genetic disorder in which multiple major aspects of senescent phenotype occur much earlier than in healthy age-matched subjects and has been often defined as an accelerated aging syndrome. The aim of this study was to compare plasma N-glycome of patients affected by DS with age- and sex matched non-affected controls, represented by their siblings (DSS), in order to assess if DS is characterized by a specific N-glycomic pattern. Therefore, in order to investigate if N-glycans changes that occur in DS were able to reveal an accelerated aging in DS patients, we enrolled the mothers (DSM) of the DS and DSS, representing the non-affected control group with a different chronological age respect to DS. We applied two different N-glycomics approaches on the same samples: first, in order to study the complete plasma N-glycome we applied a new high-sensitive protocol based on a MALDI-TOF-MS approach, second, we used DSA-FACE technology. Results: MALDI-TOF/MS analysis detected a specific N-glycomics signature for DS, characterized by an increase of fucosylated and bisecting species. Moreover, in DS the abundance of agalactosylated (as NA2F) species was similar or higher than their mothers. The measurement of GlycoAge test with DSA-FACE, validated also by MALDI-TOF, demonstrated a strongly association with age, moreover in DS, it’s value was similar to their mothers, and significantly higher than their age- and sex matched not-affected siblings Alma Mater Studiorum - Università di Bologna Franceschi, Claudio 2014-05-16 Doctoral Thesis PeerReviewed application/pdf en http://amsdottorato.unibo.it/6312/ info:eu-repo/semantics/openAccess
collection NDLTD
language en
format Doctoral Thesis
sources NDLTD
topic MED/04 Patologia generale
spellingShingle MED/04 Patologia generale
Borelli, Vincenzo <1984>
Glycomics as an innovative technology to identify biomarkers of aging
description Introduction. Glycomic analysis allows investigating on the global glycome within body fluids (as serum/plasma), this could eventually lead to identify new types of disease biomarkers, or as in this study, biomarkers of human aging studying specific aging models. Recent studies demonstrated that the plasma N-glycome is modified during human aging, suggesting that measurements of log-ratio of two serum/plasma N-glycans (NGA2F and NA2F), named GlycoAge test could provide a non-invasive biomarker of aging. Down syndrome (DS) is a genetic disorder in which multiple major aspects of senescent phenotype occur much earlier than in healthy age-matched subjects and has been often defined as an accelerated aging syndrome. The aim of this study was to compare plasma N-glycome of patients affected by DS with age- and sex matched non-affected controls, represented by their siblings (DSS), in order to assess if DS is characterized by a specific N-glycomic pattern. Therefore, in order to investigate if N-glycans changes that occur in DS were able to reveal an accelerated aging in DS patients, we enrolled the mothers (DSM) of the DS and DSS, representing the non-affected control group with a different chronological age respect to DS. We applied two different N-glycomics approaches on the same samples: first, in order to study the complete plasma N-glycome we applied a new high-sensitive protocol based on a MALDI-TOF-MS approach, second, we used DSA-FACE technology. Results: MALDI-TOF/MS analysis detected a specific N-glycomics signature for DS, characterized by an increase of fucosylated and bisecting species. Moreover, in DS the abundance of agalactosylated (as NA2F) species was similar or higher than their mothers. The measurement of GlycoAge test with DSA-FACE, validated also by MALDI-TOF, demonstrated a strongly association with age, moreover in DS, it’s value was similar to their mothers, and significantly higher than their age- and sex matched not-affected siblings
author2 Franceschi, Claudio
author_facet Franceschi, Claudio
Borelli, Vincenzo <1984>
author Borelli, Vincenzo <1984>
author_sort Borelli, Vincenzo <1984>
title Glycomics as an innovative technology to identify biomarkers of aging
title_short Glycomics as an innovative technology to identify biomarkers of aging
title_full Glycomics as an innovative technology to identify biomarkers of aging
title_fullStr Glycomics as an innovative technology to identify biomarkers of aging
title_full_unstemmed Glycomics as an innovative technology to identify biomarkers of aging
title_sort glycomics as an innovative technology to identify biomarkers of aging
publisher Alma Mater Studiorum - Università di Bologna
publishDate 2014
url http://amsdottorato.unibo.it/6312/
work_keys_str_mv AT borellivincenzo1984 glycomicsasaninnovativetechnologytoidentifybiomarkersofaging
_version_ 1716732139258511360